# Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)

> **NCT01324869** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **BIOLOGICAL:** KH902

## Key facts

- **NCT ID:** NCT01324869
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-02
- **Final completion:** 2012-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-03-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324869, "Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01324869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*